Neuromyelitis optica spectrum disorder other diagnostic studies
|
Neuromyelitis optica spectrum disorder Microchapters |
|
Differentiating Neuromyelitis optica spectrum disorder from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neuromyelitis optica spectrum disorder other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder other diagnostic studies |
|
FDA on Neuromyelitis optica spectrum disorder other diagnostic studies |
|
CDC on Neuromyelitis optica spectrum disorder other diagnostic studies |
|
Neuromyelitis optica spectrum disorder other diagnostic studies in the news |
|
Blogs on Neuromyelitis optica spectrum disorder other diagnostic studies |
|
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
Neuromyelitis optica spectrum disorder (NMOSD) is diagnosed by integrating clinical features, serum aquaporin-4 immunoglobulin G (AQP4-IgG) testing, magnetic resonance imaging (MRI), and exclusion of alternative diagnoses.[1]
The 2026 Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) guidelines endorse the 2015 International Panel for Neuromyelitis Optica Diagnosis (IPND) criteria and emphasize AQP4-IgG testing using cell-based assays.[2]
Lumbar Puncture
Neuromyelitis optica spectrum disorder evaluation commonly includes lumbar puncture (LP). The Neuromyelitis Optica Study Group (NEMOS) strongly recommends cerebrospinal fluid (CSF) analysis, although it is not mandatory under the diagnostic criteria.[3]
- Basic assessment: Include white cell count and differential, red cell count, total protein, lactate, CSF and serum glucose, and oligoclonal bands.[3]
- Inflammatory findings: In AQP4-IgG-positive NMOSD, increased CSF cell counts and protein concentrations may occur, particularly during attacks. The cellular response can include neutrophils or eosinophils.[4]
- Oligoclonal bands: CSF-restricted bands are absent in most patients with AQP4-IgG-positive NMOSD and may be transient when present.[4] Their presence should prompt careful consideration of alternative diagnoses, including multiple sclerosis, but does not by itself exclude NMOSD.[1]
For detailed antibody testing and CSF findings, see laboratory findings.
Visual Evoked Potentials
Neuromyelitis optica spectrum disorder-associated optic neuritis may produce abnormal visual evoked potentials (VEPs), including:[3]
- Delayed P100 responses, consistent with demyelination.[3]
- Reduced response amplitudes or absent responses, suggesting axonal injury.[3]
VEPs provide supportive evidence of visual pathway dysfunction; they are not sufficient to establish NMOSD independently.[1][3]
Somatosensory Evoked Potentials
Neuromyelitis optica spectrum disorder assessment may include somatosensory evoked potentials (SSEPs) as supplementary tests of sensory pathway function. NEMOS recommends these supportive investigations, although they are not formally required for diagnosis.[3]
Visual Field Testing
Neuromyelitis optica spectrum disorder-associated optic neuritis should be assessed with visual field testing, also called perimetry. Testing helps document functional impairment and assess recovery.[3]
Retinal imaging is discussed separately under other imaging findings.
Biopsy
Neuromyelitis optica spectrum disorder diagnosis usually does not require brain or spinal cord biopsy. The IPND does not recommend central nervous system biopsy for routine diagnosis. In atypical cases, expert review of available biopsy tissue may help establish the diagnosis and exclude competing disorders.[1]
References
- ↑ 1.0 1.1 1.2 1.3 Wingerchuk DM, Banwell B, Bennett JL, et al. (2015). "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders". Neurology. 85 (2): 177–189. doi:10.1212/WNL.0000000000001729. PMC 4515040. PMID 26092914.
- ↑ Yamout B, Gouider R, Al-Roughani R, et al. (2026). "Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines". CNS Drugs. 40 (3): 283–303. doi:10.1007/s40263-025-01260-x. PMID 41591715 Check
|pmid=value (help). - ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Jarius S, Aktas O, Ayzenberg I, et al. (2023). "Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis". Journal of Neurology. 270: 3341–3368. doi:10.1007/s00415-023-11634-0. PMC 10267280 Check
|pmc=value (help). - ↑ 4.0 4.1 Jarius S, Paul F, Franciotta D, et al. (2011). "Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures". Journal of the Neurological Sciences. 306 (1–2): 82–90. doi:10.1016/j.jns.2011.03.038. PMID 21550068.